Olgotrelvir: meta-analysis of COVID-19 studies

0 0.5 1 1.5+ All studies 67% 1 1K Improvement, Studies, Patients Relative Risk Hospitalization 67% 1 1K RCTs 67% 1 1K Early 67% 1 1K Olgotrelvir for COVID-19 c19early.org December 2025 Favorsolgotrelvir Favorscontrol
0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ MPR-COV-301CN Jiang (DB RCT) 67% 0.33 [0.01-8.18] oxygen 0/604 1/608 Improvement, RR [CI] Treatment Control Tau​2 = 0.00, I​2 = 0.0%, p = 0.51 Early treatment 67% 0.33 [0.01-8.18] 0/604 1/608 67% lower risk All studies 67% 0.33 [0.01-8.18] 0/604 1/608 67% lower risk 1 olgotrelvir COVID-19 study c19early.org December 2025 Tau​2 = 0.00, I​2 = 0.0%, p = 0.51 Effect extraction pre-specified(most serious outcome) Favors olgotrelvir Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ MPR-COV-301CN Jiang (DB RCT) 67% 0.33 [0.01-8.18] hosp. 0/604 1/608 Improvement, RR [CI] Treatment Control Tau​2 = 0.00, I​2 = 0.0%, p = 0.51 Early treatment 67% 0.33 [0.01-8.18] 0/604 1/608 67% lower risk All studies 67% 0.33 [0.01-8.18] 0/604 1/608 67% lower risk 1 olgotrelvir COVID-19 hospitalization result c19early.org December 2025 Tau​2 = 0.00, I​2 = 0.0%, p = 0.51 Favors olgotrelvir Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ MPR-COV-301CN Jiang (DB RCT) 67% 0.33 [0.01-8.18] oxygen 0/604 1/608 Improvement, RR [CI] Treatment Control Tau​2 = 0.00, I​2 = 0.0%, p = 0.51 Early treatment 67% 0.33 [0.01-8.18] 0/604 1/608 67% lower risk All studies 67% 0.33 [0.01-8.18] 0/604 1/608 67% lower risk 1 olgotrelvir COVID-19 serious outcome c19early.org December 2025 Tau​2 = 0.00, I​2 = 0.0%, p = 0.51 Effect extraction pre-specified(most serious outcome) Favors olgotrelvir Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ MPR-COV-301CN Jiang (DB RCT) 22% 0.78 [0.68-0.89] no recov. 604 (n) 608 (n) Improvement, RR [CI] Treatment Control Tau​2 = 0.00, I​2 = 0.0%, p = 0.00011 Early treatment 22% 0.78 [0.68-0.89] 604 (n) 608 (n) 22% lower risk All studies 22% 0.78 [0.68-0.89] 604 (n) 608 (n) 22% lower risk 1 olgotrelvir COVID-19 recovery result c19early.org December 2025 Tau​2 = 0.00, I​2 = 0.0%, p = 0.00011 Favors olgotrelvir Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ MPR-COV-301CN Jiang (DB RCT) 67% 0.33 [0.01-8.18] oxygen 0/604 1/608 Improvement, RR [CI] Treatment Control Tau​2 = 0.00, I​2 = 0.0%, p = 0.51 Early treatment 67% 0.33 [0.01-8.18] 0/604 1/608 67% lower risk All studies 67% 0.33 [0.01-8.18] 0/604 1/608 67% lower risk 1 olgotrelvir COVID-19 Randomized Controlled Trial c19early.org December 2025 Tau​2 = 0.00, I​2 = 0.0%, p = 0.51 Effect extraction pre-specified(most serious outcome) Favors olgotrelvir Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ MPR-COV-301CN Jiang (DB RCT) 67% 0.33 [0.01-8.18] oxygen 0/604 1/608 Improvement, RR [CI] Treatment Control Tau​2 = 0.00, I​2 = 0.0%, p = 0.51 Early treatment 67% 0.33 [0.01-8.18] 0/604 1/608 67% lower risk All studies 67% 0.33 [0.01-8.18] 0/604 1/608 67% lower risk 1 olgotrelvir COVID-19 peer reviewed studies c19early.org December 2025 Tau​2 = 0.00, I​2 = 0.0%, p = 0.51 Effect extraction pre-specified(most serious outcome) Favors olgotrelvir Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ MPR-COV-301CN Jiang (DB RCT) 67% 0.33 [0.01-8.18] oxygen 0/604 1/608 Improvement, RR [CI] Treatment Control MPR-COV-301CN Jiang (DB RCT) 67% 0.33 [0.01-8.18] hosp. 0/604 1/608 MPR-COV-301CN Jiang (DB RCT) 22% 0.78 [0.68-0.89] no recov. 604 (n) 608 (n) Olgotrelvir COVID-19 outcomes c19early.org December 2025 Favors olgotrelvir Favors control